Systemic lupus erythematosus, Chronic non-infectious uveitis
ROIVRoivantCatalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for Brepocitinib in Systemic lupus erythematosus, Chronic non-infectious uveitis. The expected timing is based on the latest available company guidance and may change.
w/ Priovant. 11/27/23- Topline results in SLE, failed to meet primary endpoint. Continue progressing in other indications. 4/2/24- Positive topline results in Ph2 POC in NIU; Ph3 progressing 03/03/26:- NIU remains in a Phase 3 program. 04/02/26:- Ph3 NIU topline data expected in H2 2026.
Verification
Confirm timing and program details against the company announcement or filing.